The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Open accessAbstract
BACKGROUND: Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1-2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy. METHODS: In part 1, the dose-escalation phase, we administered daratumumab at doses of 0.005 to 24 mg per kilogram of body weight. In part 2, the dose-expansion phase, 30 patients received 8 mg per kilogram of daratumumab and 42 received 16 mg per kilogram, administered once weekly (8 doses), twice monthly (8 doses), and monthly for up to 24 months. End points included safety, efficacy, and pharmacokinetics. RESULTS: No maximum tolerated dose was identified in part 1. In part 2, the median time since diagnosis was 5.7 years. Patients had received a median of four prior treatments; 79% of the patients had disease that was refractory to the last therapy received (64% had disease refractory to proteasome inhibitors and immunomodulatory drugs and 64% had disease refractory to bortezomib and lenalidomide), and 76% had received autologous stem-cell transplants. Infusion-related reactions in part 2 were mild (71% of patients had an event of any grade, and 1% had an event of grade 3), with no dose-dependent adverse events. The most common adverse events of grade 3 or 4 (in ≥ 5% of patients) were pneumonia and thrombocytopenia. The overall response rate was 36% in the cohort that received 16 mg per kilogram (15 patients had a partial response or better, including 2 with a complete response and 2 with a very good partial response) and 10% in the cohort that received 8 mg per kilogram (3 had a partial response). In the cohort that received 16 mg per kilogram, the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 8.1), and 65% (95% CI, 28 to 86) of the patients who had a response did not have progression at 12 months. CONCLUSIONS: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma. (Funded by Janssen Research and Development and Genmab; ClinicalTrials.gov number, NCT00574288.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.84–87”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab is active in relapsed, refractory multiple myeloma.85”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“After the implementation of guidelines from other studies of daratumumab regarding the management of infusion-related reactions, infusion-related reactions were consistent with daratumumab monotherapy 9,10 and combination therapy, 18,19,32 were mostly of grade 1 or 2, and usually occurred during the first infusion.”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationKumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citationSiegel, D. S. D., Martin, T. G., Wang, M. L., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 664
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma
Lin, P. Y., Owens, R., Tricot, G. J. K., & Wilson, C. S. (2004) · American Journal of Clinical Pathology · doi:10.1309/74r4tb90buwh27jx · Cited by 454
Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381
Self-citationZonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,000
Daratumumab or active monitoring for high-risk smoldering multiple myeloma
Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., Lindsay, J., Baker, R. I., Suzuki, K., Kosugi, H., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409029 · Cited by 121
Self-citationDaratumumab: First Global Approval
McKeage, K. (2016) · Drugs · doi:10.1007/s40265-015-0536-1 · Cited by 120
Ferguson, I., Patiño-Escobar, B., Tuomivaara, S. T., Lin, Y.-H. T., Nix, M. A., Leung, K., Kasap, C., Ramos, E., Vasquez, W. N., Talbot, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31810-6 · Cited by 124
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Usmani, S. Z., Nahi, H., Mateos, M., van de Donk, N. W. C. J., Chari, A., Kaufman, J. L., Moreau, P., Oriol, A., Plesner, T., Benboubker, L., et al. (2019) · Blood · doi:10.1182/blood.2019000667 · Cited by 120
Self-citationInfectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
Nahi, H., Chrobok, M., Gran, C., Lund, J., Gruber, A., Gahrton, G., Ljungman, P. T., Wagner, A. K., & Alici, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211927 · Cited by 114
Self-citationOberle, A., Brandt, A. P., Voigtlaender, M., Thiele, B., Radloff, J., Schulenkorf, A., Alawi, M., Akyüz, N., März, M., Ford, C. T., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.161414 · Cited by 110
Glucocorticoids in multiple myeloma: past, present, and future
Burwick, N. R., & Sharma, S. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3465-8 · Cited by 113
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Jelı́nek, T., Paiva, B., & Hájek, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02431 · Cited by 115
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
Plesner, T., Arkenau, H., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M. C., Lassen, U., Laubach, J. P., Palumbo, A. P., Lisby, S., et al. (2016) · Blood · doi:10.1182/blood-2016-07-726729 · Cited by 111
Self-citationImmunotherapy in hematologic malignancies: past, present, and future
Im, A., & Pavletic, S. Z. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0453-8 · Cited by 112
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
Martin, T. G., Strickland, S. A., Glenn, M. J., Charpentier, E., Guillemin, H., Hsu, K., & Mikhael, J. R. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0198-4 · Cited by 109
Usmani, S. Z., Nahi, H., Plesner, T., Weiss, B. M., Bahlis, N. J., Belch, A., Voorhees, P. M., Laubach, J. P., van de Donk, N. W. C. J., Ahmadi, T., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30081-8 · Cited by 109
Self-citationChapuy, C. I., Aguad, M. D., Nicholson, R. T., AuBuchon, J. P., Cohn, C. S., Delaney, M., Fung, M. K. Y., Unger, M., Doshi, P. D., Murphy, M. F., et al. (2016) · Transfusion · doi:10.1111/trf.13789 · Cited by 107
Management of multiple myeloma in the relapsed/refractory patient
Sonneveld, P. (2017) · Hematology · doi:10.1182/asheducation-2017.1.508 · Cited by 110
Drgoňa, Ľ., Gudiol, C., Lanini, S., Salzberger, B., Ippolito, G., & Mikulska, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.03.022 · Cited by 107
Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wäsch, R., D’Agostino, M., Scheubeck, S., Goldschmidt, H., Gay, F., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0142-9 · Cited by 108
Giri, S., Grimshaw, A. A., Bal, S., Godby, K. N., Kharel, P., Djulbegović, B., Dimopoulos, M. A., Facon, T. T. F., Usmani, S. Z., Mateos, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4338 · Cited by 107
Targeting CD38 in Refractory Extranodal Natural Killer Cell–T-Cell Lymphoma
Hari, P., Raj, R. V., & Olteanu, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1605684 · Cited by 100
Bispecific Antibodies in Multiple Myeloma: Present and Future
Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J. R., Sanchez, L. J., & Chari, A. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0028 · Cited by 102
Taylor, R. P., & Lindorfer, M. A. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.003 · Cited by 97
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab
García‐Guerrero, E., Gogishvili, T., Danhof, S., Schreder, M., Pallaud, C., Pérez‐Simón, J. A., Einsele, H., & Hudecek, M. (2017) · Blood · doi:10.1182/blood-2017-03-770776 · Cited by 96
Sun, C., Mahendravada, A., Ballard, B. C., Kale, B. J., Ramos, C. A., West, J., Maguire, T., McKay, K., Lichtman, E. I., Tuchman, S. A., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26792 · Cited by 99
Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation
Chapuy, C. I., Kaufman, R. M., Alyea, E. P., & Connors, J. M. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807438 · Cited by 97
B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma
Tai, Y., & Anderson, K. C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1641196 · Cited by 94
Efficacy of Panobinostat for the Treatment of Multiple Myeloma
Eleutherakis‐Papaiakovou, E., Kanellias, N., Kastritis, E., Gavriatopoulou, M., Terpos, E., & Dimopoulos, M. A. (2020) · Journal of Oncology · doi:10.1155/2020/7131802 · Cited by 92
Bahlis, N. J., Baz, R., Harrison, S. J., Quach, H., Ho, S.-J., Vangsted, A. J., Plesner, T., Moreau, P., Gibbs, S. D., Coppola, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00443 · Cited by 91
Self-citationLandgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0718-z · Cited by 102
Nooka, A. K., Joseph, N. S., Kaufman, J. L., Heffner, L. T., Gupta, V. A., Gleason, C. L., Boise, L., & Lonial, S. (2019) · Cancer · doi:10.1002/cncr.32178 · Cited by 91
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells
Sullivan, H. C., Gerner‐Smidt, C., Nooka, A. K., Arthur, C. M., Thompson, L., Mener, A., Patel, S. R., Yee, M. E. M., Fasano, R. M., Josephson, C. D., et al. (2017) · Blood · doi:10.1182/blood-2016-11-749432 · Cited by 90
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
Viola, D., Donà, A., Caserta, E., Troadec, E., Besi, F., McDonald, T., Ghoda, L. Y., Gunes, E. G., Sanchez, J. F., Khalife, J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0810-4 · Cited by 90
A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients
Li, C., Phoon, Y. P., Karlinsey, K. S., Tian, Y. F., Thapaliya, S., Thongkum, A., Qu, L., Matz, A., Cameron, M. J., Cameron, C., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202084 · Cited by 88
Anti CD38 monoclonal antibodies for multiple myeloma treatment
Gozzetti, A., Ciofini, S., Simoncelli, M., Santoni, A., Pacelli, P., Raspadori, D., & Bocchia, M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2052658 · Cited by 89
Merino‐Vico, A., Frazzei, G., van Hamburg, J. P., & Tas, S. W. (2022) · European Journal of Immunology · doi:10.1002/eji.202149675 · Cited by 93
Clemens, P. L., Yan, X., Lokhorst, H. M., Lonial, S., Losic, N., Khan, I., Jansson, R., Ahmadi, T., Lantz, K. A., Zhou, H., et al. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0477-1 · Cited by 88
Self-citationThe expansion of targetable biomarkers for CAR T cell therapy
Townsend, M. H., Shrestha, G., Robison, R. A., & O'Neill, K. L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0817-0 · Cited by 90
Kimmich, C. R., Terzer, T., Benner, A., Dittrich, T., Veelken, K., Carpinteiro, A., Hansen, T., Goldschmidt, H., Seckinger, A., Hose, D., et al. (2020) · Blood · doi:10.1182/blood.2019003633 · Cited by 88
Emerging agents and regimens for multiple myeloma
Yang, Y., Li, Y., Gu, H., Dong, M., & Cai, Z. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00980-5 · Cited by 87
Daratumumab for treatment‐refractory antibody‐mediated diseases in neurology
Scheibe, F., Ostendorf, L., Prüß, H., Radbruch, H., Aschman, T., Hoffmann, S., Blau, I., Meisel, C., Alexander, T., & Meisel, A. (2022) · European Journal of Neurology · doi:10.1111/ene.15266 · Cited by 88
Ogiya, D., Liu, J., Ohguchi, H., Kurata, K., Samur, M. K., Tai, Y.-T., Adamia, S., Ando, K., Hideshima, T., & Anderson, K. C. (2020) · Blood · doi:10.1182/blood.2019004332 · Cited by 92
Jagannath, S., Lin, Y., Goldschmidt, H., Reece, D., Nooka, A., Senin, A., Rodriguez-Otero, P., Powles, R., Matsue, K., Shah, N., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00507-2 · Cited by 90
Liu, Z., Zhang, J., Liu, H., Shen, H., Meng, N., Qi, X., Ding, K., Song, J., Fu, R., Ding, D., et al. (2022) · Advanced Materials · doi:10.1002/adma.202208692 · Cited by 86
Zand, L., Rajkumar, S. V., Leung, N., Sethi, S. M., Ters, M. E., & Fervenza, F. C. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020101541 · Cited by 86
Dimopoulos, M. A., Bringhen, S., Anttila, P., Capra, M., Cavo, M., Cole, C. E., Gasparetto, C., Hungria, V., Jenner, M. W., Vorobyev, V. I., et al. (2020) · Blood · doi:10.1182/blood.2020008209 · Cited by 84
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies
Bianchi, G., Zhang, Y., & Comenzo, R. L. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.09.003 · Cited by 83
Liu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.-T., Hideshima, T., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0205-y · Cited by 83
Richardson, P. G. G., Bringhen, S., Voorhees, P. M., Plesner, T., Mellqvist, U., Reeves, B., Paba‐Prada, C. E., Zubair, H., Byrne, C., Chauhan, D., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30044-2 · Cited by 83
Self-citationThe Immune Regulatory Role of Adenosine in the Tumor Microenvironment
Xing, J., Zhang, J., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914928 · Cited by 96
Self-citationvan de Donk, N. W. C. J., Otten, H. G., Haddad, O. E., Axel, A. E., Sasser, A. K., Croockewit, S., & Jacobs, J. F. M. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0888 · Cited by 82
Self-citationRaab, M. S., Engelhardt, M. M., Blank, A., Goldschmidt, H., Agis, H., Blau, I. W., Einsele, H., Ferstl, B., Schub, N., Röllig, C., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30249-2 · Cited by 82
Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies
Zhu, Y., Liu, J., Park, J., Rai, P., & Zhai, R. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.002 · Cited by 82
How I treat myeloma with new agents
Moreau, P. (2017) · Blood · doi:10.1182/blood-2017-05-743203 · Cited by 87
Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt, H., Ashcroft, J., Szabó, Z. R., & Garderet, L. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3546-8 · Cited by 81
Systemic amyloidosis: novel therapies and role of biomarkers
Nuvolone, M., & Merlini, G. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw305 · Cited by 79
Beyond pan-B-cell-directed therapy — new avenues and insights into the pathogenesis of SLE
Dörner, T., & Lipsky, P. E. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.158 · Cited by 80
Rombouts, M. D., Swart, E. L., van den Eertwegh, A. J. M., & Crul, M. (2020) · Anticancer Research · doi:10.21873/anticanres.14062 · Cited by 80
Multiple Myeloma Therapy: Emerging Trends and Challenges
Dima, D., Jiang, D., Singh, D. J., Hasipek, M., Shah, H., Ullah, F., Khouri, J., Maciejewski, J. P., & Jha, B. K. (2022) · Cancers · doi:10.3390/cancers14174082 · Cited by 92
Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma
Caserta, E., Chea, J., Minnix, M., Poku, E. K., Viola, D., Vonderfecht, S. L., Yazaki, P. J., Crow, D. M., Khalife, J., Sanchez, J. F., et al. (2018) · Blood · doi:10.1182/blood-2017-09-807263 · Cited by 76
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C. L., Djulbegović, B., Fung, H. C., Gasparetto, C., Godby, K. N., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0046 · Cited by 75
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells
An, N., Hou, Y. N., Zhang, Q. X., Li, T., Zhang, Q. L., Fang, C., Chen, H., Lee, H. C., Zhao, Y. J., & Du, X. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00584 · Cited by 77
Frerichs, K. A., Bosman, P. W. C., van Velzen, J. F., Fraaij, P. L. A., Koopmans, M., Rimmelzwaan, G. F., Nijhof, I. S., Bloem, A. C., Mutis, T., Zweegman, S., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.231860 · Cited by 74
Spencer, A. G., Harrison, S. J., Zonder, J. A., Badros, A. Z., Laubach, J. P., Bergin, K., Khot, A. S., Zimmerman, T. M., Chauhan, D., Levin, N., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14987 · Cited by 73
Self-citationActors on the Scene: Immune Cells in the Myeloma Niche
Leone, P., Solimando, A. G., Malerba, E., Fasano, R., Buonavoglia, A., Pappagallo, F., Re, V. D., Argentiero, A., Silvestris, N., Vacca, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.599098 · Cited by 73
Costa, F., Toscani, D., Chillemi, A., Quarona, V., Bolzoni, M., Marchica, V., Vescovini, R., Mancini, C., Martella, E. M., Campanini, N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17896 · Cited by 73
Moreau, P., Dimopoulos, M. A., Yong, K., Mikhael, J. R., Risse, M., Asset, G., & Martin, T. G. (2019) · Future Oncology · doi:10.2217/fon-2019-0431 · Cited by 72
Murata, K., McCash, S. I., Carroll, B. L., Lesokhin, A. M., Hassoun, H., Lendvai, N. K., Korde, N., Mailankody, S., Landau, H. J., Koehne, G., et al. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.09.015 · Cited by 71
Bu, D., Singh, R., Choi, E., Ruella, M., Nuñez-Cruz, S., Mansfield, K. G., Bennett, P., Barton, N., Wu, Q., Zhang, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25359 · Cited by 74
Richardson, P. G. G., Attal, M., Campana, F., Le-Guennec, S., Hui, A., Risse, M., Corzo, K. P., & Anderson, K. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0616 · Cited by 71
Self-citationLong-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
Oberle, A., Brandt, A. P., Alawi, M., Langebrake, C., Janjetovic, S., Wolschke, C., Schütze, K., Bannas, P., Kröger, N. M., Koch‐Nolte, F., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.169235 · Cited by 69
Daratumumab for the Treatment of Multiple Myeloma
Plesner, T., & Krejcik, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01228 · Cited by 68
Self-citationFumey, W., Koenigsdorf, J., Kunick, V., Menzel, S., Schütze, K., Unger, M., Schriewer, L., Haag, F., Adam, G., Oberle, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14112-6 · Cited by 69
Selinexor for the treatment of multiple myeloma
Podar, K., Shah, J. J., Chari, A., Richardson, P. G. G., & Jagannath, S. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1707184 · Cited by 68
Self-citationXu, X., Yan, X., Puchalski, T. A., Lonial, S., Lokhorst, H. M., Voorhees, P., Plesner, T. L., Liu, K., Khan, I., Jansson, R., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.577 · Cited by 67
Self-citationEmerging Therapies in Immune Thrombocytopenia
Audia, S., & Bonnotte, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051004 · Cited by 68
Mericskay, M. (2015) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2015.10.004 · Cited by 69
Immune Therapies in Multiple Myeloma
Kumar, S. K., & Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0868 · Cited by 66
How I treat first relapse of myeloma
Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 67
Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives
Schrezenmeier, E. V., Jayne, D. R. W., & Dörner, T. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017040367 · Cited by 68
Immunotherapy in myeloma: how far have we come?
Franssen, L. E., Mutis, T., Lokhorst, H. M., & van de Donk, N. W. C. J. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718822660 · Cited by 66
Self-citationHuang, H., Zhu, J., Yao, M., Kim, T. M., Yoon, D. H., Cho, S., Eom, H., Lim, S. T., Yeh, S., Song, Y., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01020-y · Cited by 66
A clinical perspective on plasma cell leukemia; current status and future directions
Tuazon, S. A., Holmberg, L., Nadeem, O., & Richardson, P. G. G. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00414-6 · Cited by 68
Self-citationDíaz-Tejedor, A., Lorenzo-Mohamed, M., Puig, N., García‐Sánz, R., Mateos, M., Garayoa, M., & Paíno, T. (2021) · Cancers · doi:10.3390/cancers13061353 · Cited by 66
Desensitization strategies in adult heart transplantation—Will persistence pay off?
Chih, S., & Patel, J. K. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.03.021 · Cited by 64
Whither Radioimmunotherapy: To Be or Not To Be?
Green, D. J., & Press, O. W. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2523 · Cited by 64
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Cuesta‐Mateos, C., Alcaraz‐Serna, A., Somovilla-Crespo, B., & Muñoz‐Calleja, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01936 · Cited by 65
Ninety-minute daratumumab infusion is safe in multiple myeloma
Barr, H., Dempsey, J. L., Waller, A., Huang, Y., Williams, N., Sharma, N., Benson, D. M., Rosko, A. E., Efebera, Y. A., & Hofmeister, C. C. (2018) · Leukemia · doi:10.1038/s41375-018-0120-2 · Cited by 63
Solimando, A. G., Vià, M. D., Cicco, S., Leone, P., Lernia, G. D., Giannico, D., Desantis, V., Frassanito, M. A., Morizio, A., Tascon, J. D., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070997 · Cited by 61
Usmani, S. Z., Nahi, H., Legiec, W. M., Grosicki, S., Vorobyev, V. I., Špıčka, I., Hungria, V., Korenkova, S., Bahlis, N. J., Flogegård, M., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.279459 · Cited by 64
Self-citationDaratumumab for autoimmune diseases: a systematic review
Holzer, M., Ruffer, N., Huber, T. B., Kötter, I., Ostendorf, L., & Krusche, M. (2023) · RMD Open · doi:10.1136/rmdopen-2023-003604 · Cited by 62
Gene Expression Profiles in Myeloma: Ready for the Real World?
Szalat, R. E., Avet‐Loiseau, H., & Munshi, N. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0867 · Cited by 64
Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
Ghose, J., Viola, D., Terrazas, C. A., Caserta, E., Troadec, E., Khalife, J., Gunes, E. G., Sanchez, J. F., McDonald, T., Marcucci, G., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1486948 · Cited by 63
BCMA in Multiple Myeloma—A Promising Key to Therapy
Kleber, M., Ntanasis‐Stathopoulos, I., & Terpos, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184088 · Cited by 63
Zhang, Z., Xu, Q., & Huang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126421 · Cited by 62
Monoclonal antibody therapy in multiple myeloma
Touzeau, C., Moreau, P., & Dumontet, C. (2017) · Leukemia · doi:10.1038/leu.2017.60 · Cited by 61
Green, D. J., O’Steen, S., Lin, Y., Comstock, M., Kenoyer, A. L., Hamlin, D. K., Wilbur, D. S., Fisher, D. R., Nartea, M. E., Hylarides, M. D., et al. (2017) · Blood · doi:10.1182/blood-2017-09-807610 · Cited by 62
Mohan, M., Weinhold, N., Schinke, C., Thanedrarajan, S., Rasche, L., Sawyer, J. R., Tian, E., van Rhee, F., & Zangari, M. (2019) · British Journal of Haematology · doi:10.1111/bjh.16292 · Cited by 61
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
Davis, L. N., & Sherbenou, D. W. (2021) · Cancers · doi:10.3390/cancers13071686 · Cited by 63
Chimeric Antigen Receptor ( CAR ) therapy for multiple myeloma
Atanackovic, D., Radhakrishnan, S. V., Bhardwaj, N., & Luetkens, T. (2016) · British Journal of Haematology · doi:10.1111/bjh.13889 · Cited by 60
Xing, L., Lin, L., Yu, T., Li, Y., Cho, S., Liu, J., Wen, K., Hsieh, P. A., Kinneer, K., Munshi, N. C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0745-9 · Cited by 61
Allogeneic stem cell transplantation for multiple myeloma: is there a future?
Dhakal, B., Vesole, D. H., & Hari, P. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.325 · Cited by 61
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
Abramson, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123924 · Cited by 59
Metadata
- Authors
- Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N. W. C. J., Ahmadi, T., Khan, I., Uhlar, C. M., Wang, J., Sasser, A. K., Losic, N., Lisby, S., Basse, L., Brun, N., & Richardson, P. G.
- Affiliations
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Harvard University (US)
- Karolinska University Hospital (SE)
- Lund University (SE)
- University Medical Center Utrecht (NL)
- University of Turin (IT)
- Janssen Research & Development (United States) (US)
- Genmab (Denmark) (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-09-24
- Volume
- 373
- Issue
- 13
- Pages
- 1207-1219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1902692042
- Semantic Scholar
- c731f1036338cb22a95a42420cb4ccf650d6c359
- Cited by
- 1,117
- References
- 27
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 63 · 2023: 87 · 2022: 83 · 2021: 134 · 2020: 131 · 2019: 108 · 2018: 129 · 2017: 125 · 2016: 143 · 2015: 14
- FWCI
- 107.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, daratumumab, CD38, monoclonal antibodies, relapsed/refractory multiple myeloma, monotherapy, dose escalation, progression-free survival, overall response rate, infusion reactions, pharmacokinetics, autologous stem cell transplantation, lenalidomide-refractory disease, bortezomib-refractory disease, pneumonia, thrombocytopenia, complete response, very good partial response
- MeSH terms
- Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Multiple Myeloma, Pneumonia, Thrombocytopenia, Disease-Free Survival, Drug Resistance, Neoplasm, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
